Hims & Hers Health (NYSE: HIMS) reports Q2 2026 earnings Monday August 10, 2026 after market close under the shadow of the July 29, 2026 Federal Trade Commission (FTC) lawsuit. FTC allegations: the company shared consumer sensitive health information with Meta Platforms, Snap Inc., and other online advertising platforms through embedded website tracking technologies (pixel-based cookie/session tracking) without meeting informed-consent requirements; and separately, that the company charged some patients for prescriptions they did not order. Los Angeles County and Utah joined the FTC as co-plaintiffs, expanding both the geographic exposure and the potential remedy set. HIMS shares dropped 10% on the July 29 announcement. Bank of America analyst Allen Lutz reiterated Hold and cut the price target to $30 from $37 on FTC-lawsuit uncertainty, characterizing the outcome as a small-fee base case. Wall Street consensus for Q2 2026: $698.9 million revenue (+28.3% year-over-year) and -$0.05 diluted EPS loss versus the +$0.17 year-ago quarter. Options traders are pricing an approximate 14.5% post-earnings move in either direction. Analyst focus areas: peptide-compounding revenue trajectory (Leerink pegs $440M peptide sales for full-year 2026), FTC lawsuit financial and operational impact, and branded GLP-1 partnership contribution since Q1 2026.
Hims & Hers Health (NYSE: HIMS) reports Q2 2026 earnings Monday August 10, 2026 after market close under the shadow of a Federal Trade Commission (FTC) lawsuit alleging the company shared consumer sensitive health information with third-party advertising platforms without meeting HIPAA-compatible informed-consent requirements. Wall Street consensus: $698.9 million revenue (+28.3% year-over-year) and approximately -$0.05 diluted EPS loss versus +$0.17 EPS in the year-ago quarter. Bank of America analyst Allen Lutz cut the HIMS price target to $30 from $37 (maintaining Hold), citing FTC-lawsuit uncertainty with a small-fee base-case framing. Options traders are pricing an approximate 14.5% post-earnings move in either direction. Analyst focus areas beyond top-line numbers: post-PCAC peptide-compounding revenue trajectory (Leerink estimates $440 million peptide sales in 2026 representing 15% of the projected revenue midpoint); FTC lawsuit financial and operational impact; branded GLP-1 (Wegovy/Ozempic/Zepbound/Mounjaro) commercial partnership contribution since Q1 2026; and Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC harm-reduction testimony framing for the Hims peptide strategy narrative. Truist analysts have cautioned that substantial peptide revenue is unlikely before 2028 even with the PCAC advisory support given the 12-24 month FDA rulemaking timeline.
Post-PCAC analyst coverage of Hims & Hers Health (NYSE: HIMS) split on the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 outcome. BofA Securities raised its price target to $36 on the peptide-compounding opportunity, and Canaccord Genuity raised to $40, both citing the July 23-24 PCAC vote and the Hims & Hers acquired California peptide manufacturing facility. Analysts estimate the four Day-1 recommended peptides (BPC-157, KPV, TB-500, MOTS-c) could generate approximately $440 million in Hims & Hers sales by 2027 if the FDA follows through with 503A rulemaking. Truist Securities held at $23 citing the 6-18 month FDA rulemaking timeline and continued uninsured-patient exposure. Barclays sits at $39 (Novo Nordisk partnership thesis). The peptide catalyst lift is tempered by the advisory-vote nature of the PCAC outcome: compounding pharmacies still cannot legally prepare BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon under Section 503A today because none of the six substances are on the 503A Bulks List. FDA rulemaking to add each substance takes 6-18 months from the date the agency decides to act. Hims shares closed near $28.50 last week after briefly rallying above $35 on the initial vote outcome.
Analyst dispersion around Hims & Hers Health (NYSE: HIMS) widened this week following the FDA career-staff briefing documents released June 29-30 concluding all seven PCAC peptides have insufficient evidence for 503A bulks-list inclusion. The four fresh price targets span nearly two-to-one: Truist Securities reiterated a Hold rating with a $23 price target, citing near-term-performance strength tempered by uncertainty around peptide-compounding regulation. BofA Securities raised its price target to $36 from $25 while maintaining Neutral, noting the FDA update is negative for the company's peptide-optionality narrative but not the core weight-loss business. Barclays' Glen Santangelo raised to $39 from $29 while maintaining Overweight, crediting improvements from the renewed Novo Nordisk partnership. Canaccord's Maria Ripps raised to $40 from $32 while maintaining Buy, citing the company's transition from compounded to branded weight-loss drugs. The 74% spread from lowest to highest target reflects analyst disagreement about how much of the Hims growth story now runs through peptide optionality versus branded-GLP-1 rails.
Multiple Wall Street firms raised LLY price targets in the May 5–6 window. Cantor Fitzgerald lifted its target to $1,230, BofA to $1,294, and the broader analyst consensus by 19 firms now sits at $1,228 (24.15% upside over 12 months) per the May 6 update, with a Buy consensus rating. The driver: tirzepatide's Q1 +125% global growth, the Mounjaro/Zepbound volume re-rating, the May 1 stock recovery from the Foundayo hepatic-failure FAERS report, and Lilly's response that no DILI signal exists across the 11,000-patient ACHIEVE+ATTAIN program. RBC Capital framed the FAERS event as 'baseline noise.'